STALLION NSE filing

Stallion India Fluorochemicals Ltd. Presents Investor Presentation for Q2 & H1 FY27

The RealCase readHigh impact Positive

Stallion India Fluorochemicals released its Q2 & H1 FY27 investor presentation. Key developments include the operational start of the Khalapur High-Purity Helium Facility and plans for a new Mambattu facility. The company is also building a 10,000 MT R-32 manufacturing plant in Bhilwara, Rajasthan, with expected commissioning in March 2027. These initiatives aim to boost EBITDA margins and support a projected 30-35% CAGR over the next three years.

Why it matters

The announcement details substantial capacity expansions, entry into new high-value segments like high-purity helium and HFOs, and backward integration plans, which are expected to significantly impact the company's revenue, profitability, and market position.

The market read

The company is reporting significant operational expansions, strategic partnerships, and regulatory approvals for new manufacturing facilities, all of which are positive indicators for future growth and profitability.

Stallion India Fluorochemicals Limited has released an investor presentation detailing its financial results for the quarter and half-year ended September 30, 2026. The presentation highlights the company's strategic growth initiatives, including the commencement of operations at its Khalapur High-Purity Helium Facility in September 2026 with a capacity of 1,200 MT per annum. This facility marks the company's entry into the high-value specialty gases segment, serving industries like semiconductors, healthcare, and aerospace.

Further expansion plans include the upcoming Mambattu facility in Andhra Pradesh to strengthen its distribution network across South India. The company is also progressing towards backward integration with a proposed 10,000 MT R-32 manufacturing facility at Bhilwara, Rajasthan, with construction planned to begin in 2027. These initiatives are expected to enhance manufacturing capabilities, improve cost efficiencies, and strengthen supply chain reliability.

The company anticipates that its focus on next-generation HFOs, specialty gases, high-purity helium, and semiconductor-related gases will support its entry into higher-value markets. These strategic moves are projected to strengthen the product mix and improve EBITDA margins by approximately 3-4% over the medium term.

The presentation also provides an overview of the company's established facilities, core business metrics, key milestones, and its presence across various major industries. It details strategic expansions into HFO manufacturing and the high-purity helium segment, including a long-term strategic sourcing partnership for liquid helium. Financial highlights showcase revenue growth, EBITDA, and PAT figures for FY23-24 to FY25-26, along with quarterly performance for Q2 FY26 and Q2 FY27, and H1 FY26 and H1 FY27, demonstrating significant improvements in operating metrics before ESOP provisions.

A significant regulatory milestone is the receipt of Environmental Clearance (EC) from SEIAA, Rajasthan, on December 28, 2025, for the proposed 10,000 MT R-32 manufacturing facility at Bhilwara, Rajasthan. Construction has commenced, with commissioning expected by March 2027. This project is estimated to have a topline potential of ₹500-600 crore in FY27-28 and an expected PAT margin of 22%. The company forecasts a 30-35% CAGR for the next three years, maintaining sustainable margins.

Filing to action

What to do with a filing like this

Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.

View original filing